These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 25062617)

  • 21. Successes and limitations of targeted cancer therapy in breast cancer.
    Curigliano G; Criscitiello C
    Prog Tumor Res; 2014; 41():15-35. PubMed ID: 24727984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New in silico and conventional in vitro approaches to advance HIV drug discovery and design.
    Maga G; Veljkovic N; Crespan E; Spadari S; Prljic J; Perovic V; Glisic S; Veljkovic V
    Expert Opin Drug Discov; 2013 Jan; 8(1):83-92. PubMed ID: 23167743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay.
    Al-Sha'er MA; Taha MO
    Eur J Med Chem; 2010 Sep; 45(9):4316-30. PubMed ID: 20638755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting unimolecular G-quadruplex nucleic acids: a new paradigm for the drug discovery?
    Parrotta L; Ortuso F; Moraca F; Rocca R; Costa G; Alcaro S; Artese A
    Expert Opin Drug Discov; 2014 Oct; 9(10):1167-87. PubMed ID: 25109710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational methods to identify new antibacterial targets.
    McPhillie MJ; Cain RM; Narramore S; Fishwick CW; Simmons KJ
    Chem Biol Drug Des; 2015 Jan; 85(1):22-9. PubMed ID: 24974974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mathematical modeling of efficacy and safety for anticancer drugs clinical development.
    Lavezzi SM; Borella E; Carrara L; De Nicolao G; Magni P; Poggesi I
    Expert Opin Drug Discov; 2018 Jan; 13(1):5-21. PubMed ID: 28972401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genome-scale modeling of human metabolism - a systems biology approach.
    Mardinoglu A; Gatto F; Nielsen J
    Biotechnol J; 2013 Sep; 8(9):985-96. PubMed ID: 23613448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of drug candidates and repurposing opportunities through compound-target interaction networks.
    Cichonska A; Rousu J; Aittokallio T
    Expert Opin Drug Discov; 2015 Dec; 10(12):1333-45. PubMed ID: 26429153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Informatics resources for tuberculosis--towards drug discovery.
    Sundaramurthi JC; Brindha S; Reddy TB; Hanna LE
    Tuberculosis (Edinb); 2012 Mar; 92(2):133-8. PubMed ID: 21943870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
    Vari S; Pilotto S; Maugeri-Saccà M; Ciuffreda L; Cesta Incani U; Falcone I; Del Curatolo A; Ceribelli A; Gelibter A; De Maria R; Tortora G; Cognetti F; Bria E; Milella M
    Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Support vector machines for drug discovery.
    Heikamp K; Bajorath J
    Expert Opin Drug Discov; 2014 Jan; 9(1):93-104. PubMed ID: 24304044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The multi-target capabilities of the compounds in a TCM used to treat sepsis and their in silico pharmacology.
    Ma S; Feng C; Zhang X; Dai G; Li C; Cheng X; Liu P; Ju W; Yu H
    Complement Ther Med; 2013 Feb; 21(1):35-41. PubMed ID: 23374203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemogenomic approaches to infer drug-target interaction networks.
    Yamanishi Y
    Methods Mol Biol; 2013; 939():97-113. PubMed ID: 23192544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systems pharmacology strategies for drug discovery and combination with applications to cardiovascular diseases.
    Li P; Chen J; Wang J; Zhou W; Wang X; Li B; Tao W; Wang W; Wang Y; Yang L
    J Ethnopharmacol; 2014; 151(1):93-107. PubMed ID: 23850710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel drugs for promising targets.
    Martell RE; Brooks DG; Wang Y; Wilcoxen K
    Clin Ther; 2013 Sep; 35(9):1271-81. PubMed ID: 24054704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based approaches to antibiotic drug discovery.
    Nicola G; Abagyan R
    Curr Protoc Microbiol; 2009 Feb; Chapter 17():Unit17.2. PubMed ID: 19235149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.
    Hollebecque A; Massard C; Soria JC
    Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioinformatics Approaches for Anti-cancer Drug Discovery.
    Li K; Du Y; Li L; Wei DQ
    Curr Drug Targets; 2020; 21(1):3-17. PubMed ID: 31549592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the approach to novel drug clinical development for breast cancer.
    Ferrario C; Batist G
    Expert Opin Drug Discov; 2014 Jun; 9(6):647-68. PubMed ID: 24758225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.